Implementing an intra outbreak ring vaccination clinical trial for Sudan Ebola virus disease within four days of outbreak notification in Uganda.
Emerging microbes & infections·
- DOI
- 10.1080/22221751.2026.2731496
- PMID
- 42703692
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Publisher unavailable
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The four-day turnaround provides a replicable blueprint for rapid medical countermeasure evaluation during future outbreaks in settings with heightened Ebola Virus Disease threat. The approach demonstrates that prepositioned protocols, established infrastructure, and trained personnel can dramatically compress trial activation timelines.
Structured evidence summary
Research question
The study documents the operational feasibility of launching a ring vaccination trial for Sudan ebolavirus within four days of outbreak notification in Uganda.
Study design
This is a descriptive report of the mobilization process for an intra-outbreak ring vaccination clinical trial, detailing the sequence of activities from outbreak declaration on January 30, 2025, through trial launch four days later.
Population and setting
The trial was conducted in Uganda following the January 2025 Sudan Virus Disease outbreak declaration. Field and community engagement personnel were mobilized and deployed to affected areas.
Main findings
The investigation team achieved trial launch within four days by activating prefinancing mechanisms, utilizing a prepositioned research protocol for rapid ethics and regulatory clearance, accessing investigation product already in-country, and deploying previously trained personnel with refresher training. The rapid response was enabled by research, logistical, and staffing infrastructure established during the 2022 Sudan Virus Disease outbreak in Uganda.
Public-health relevance
The four-day turnaround provides a replicable blueprint for rapid medical countermeasure evaluation during future outbreaks in settings with heightened Ebola Virus Disease threat. The approach demonstrates that prepositioned protocols, established infrastructure, and trained personnel can dramatically compress trial activation timelines.
Important limitations
This summary relies on the supplied single-article abstract and metadata. The original paper is required for decision-grade interpretation of trial outcomes, vaccine safety and efficacy data, enrollment numbers, and operational constraints encountered during the mobilization.
GIDS interpretation
The article is discoverable through Ebola, outbreak investigation, vaccination, and treatment topics, with geographic links to Uganda, Sudan, and Democratic Republic of the Congo. It addresses operational research on outbreak response rather than epidemiologic surveillance or disease transmission dynamics.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.